TechnoMedica Raises H1 Profit Forecast on Consumables Demand
TechnoMedica (TSE:6678) has raised its earnings guidance for the six months ending September 30, 2026, citing stronger-than-expected consumables sales and delayed R&D spending.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue | JPY 4.27bn | JPY 4.36bn | +2.1% |
| Operating Profit | JPY 170M | JPY 300M | +76.5% |
| Ordinary Income | JPY 170M | JPY 310M | +82.4% |
| 中間純利益 | JPY 120M | JPY 220M | +83.3% |
| １株当たり中間純利益 | JPY 17.40/share | JPY 31.90/share | +83.3% |
The medical technology company attributed the upward revision to increased sales of consumables in both domestic and overseas markets, combined with a slower-than-anticipated pace of research and development expenditures. The timing delay in R&D spending has reduced selling, general and administrative expenses in the interim period.
The company emphasized that the interim-period profit gains will not extend to full-year results, leaving its fiscal 2027 full-year guidance unchanged. Dividend forecasts also remain unrevised. The interim profit uplift reflects timing benefits rather than structural business improvement, suggesting investors should await full-year results for confirmation of sustained momentum. The company maintains its original full-year outlook despite the strong interim showing.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.